77 results about "Paroxysmal AF" patented technology

Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and / or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.

The invention discloses a traditional Chinese medicine combination and a preparation method thereof for chronic enteritis treatment; the traditional Chinese medicine combination mainly includes the following raw medicines: crude radix astragali, Chinese yam, bighead atractylodes rhizome, rhizoma smilacis glabrae, honeysuckle, taraxacum officinale root, medicated leaven, burnt malt, atraotydin, mangnolia officinalis, dried tangerine or orange peel, plantain seed, scutellaria baicalensis, the rhizome of Chinese goldthread, limonite, semen euryales, fructus rosae laevigatae, liriope, fructus amomi, starwort root, schisandra, acorus gramineus, medlar, cyperus rotundus and the like The traditional Chinese medicine combination can be prepared into any type of common oral preparation according to the conventional traditional Chinese medicine preparation method. The invention can significantly improve the symptoms of chronic diarrhea, paroxysmal abdominal pain, dyspepsia, indigestion, loose stool, abdominal distension, emaciation, limb fatigue and doldrums, and also has definite clinical curative effect, significant curative and quick effect. As the traditional Chinese medicine combination basically combines medicinal and edible medicine sources specified in the National Formulary, the traditional Chinese medicine combination has low cost and basically has no toxic and side effect.

A device including circuits able to control the switching of a AAI mode in a DDD mode, and conversely the return of DDD mode to AAI mode, according to predetermined criteria of detection of atrio-ventricular block (AVB) of the first, second, or third degree and of ventricular pause. The device includes moreover circuits for detecting state, able to diagnose at least a specific temporary state of the patient, in particular a state of effort or sleep, and the circuits for mode switching operate in response to these circuits for detecting state to modify selectively, for the length of time when the aforementioned state is diagnosed, the criteria of switching from AAI mode towards DDD mode and / or the criteria of return to AAI mode, and / or the criteria of final commutation in DDD mode.

Immunosorbents, kits and compositions for diagnosing a central nervous system disorder, particularly paroxysmal cerebral discharges and epilepsy, comprising measuring the concentration of GluR1 or fragment thereof and / or GluR1 antibodies in a biological sample from a human subject. The method is particularly useful for identifying individuals that are at risk for brain related seizures and epilepsy, for distinguishing epilepsy from pseudo-epilepsy and epilepsy-like disorders, for following up after anticonvulsive treatment, and for the adjustment of adequate therapy and doses.

This invention provides methods for alleviating paroxysmal disorders in an animal, particularly epilepsy, by modulating glycolysis in brain cells.

This invention provides methods for alleviating paroxysmal disorders in an animal, particularly epilepsy, by modulating glycolysis in brain cells.

A method for alleviating the dizziness symptoms of a person suffering from benign paroxysmal positional vertigo comprising the steps of: positioning the head of the person on a head-rest device that is formed of a first pillow structure; a second pillow structure with at least one slanted surface; and a non-permanent fastener on at least one surface of the first pillow structure and one surface of the second pillow structure so that the first and the second pillow can be placed in a user-selected configuration one on top of the other and the relative positions of the first pillow structure to the second pillow structure is fixed by the non-permanent fastener. The second pillow structure overhangs the first pillow structure so as to define an overhang region. The method includes the step of adjusting the second pillow structure so as to position a sleeping surface of the second pillow structure at an angle between about 20 degrees and 60 degrees relative to a horizontal reference surface. The overhang region is configured to receive a head and neck region of the person.

The invention discloses an intelligent analysis method and system of paroxysmal atrial fibrillation based on a difference time scatter diagram. The method includes a training stage and a detection stage; the training stage includes the steps: A1) collecting original ECG training data; A2) drawing the difference time scatter diagram of the training stage; A3) labeling the difference time scatter diagram with an atrial fibrillation attack label and a non-atrial fibrillation attack label; and A4) training a convolution neural network model. The detection stage includes the steps: B1) collecting original ECG detection data; B2) drawing the difference time scatter diagram of the detection stage; and B3) inputting the difference time scatter diagram of the detection stage to the convolution neural network model and outputting intelligent analysis results of paroxysmal atrial fibrillation. The intelligent diagnosis of paroxysmal atrial fibrillation can be realized and the detection of subclinical atrial fibrillation patients can be realized by using the method for classification by the differential time scatter diagram.

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement factor B (CFB) gene, the complement component C3 gene, and the complement component C9 gene and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of CFB, C9 and / or C3 and to treat subjects having a complement component-associated disease, e.g., paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

Provided herein are methods for treating a subject with PNH comprising administering to a subject a therapeutically effective amount of complement component C5 (C5) inhibitor, complement component C3 (C3) inhibitor, or complement factor B (CFB) inhibitor in combination with a therapeutically effective amount of small molecule complement factor D (CFD) inhibitor of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.

A heart stimulator has a stimulation energy delivering assembly, including at least one lead adapted for implantation in contact with cardiac tissue, and an atrial arrhythmia detector, and a control unit connected to the stimulation energy delivering assembly and to the detector. The control unit controls the stimulation energy delivering assembly to deliver at least one atrial arrhythmia abolishing therapy and, if continued atrial arrhythmia is detected, to deliver antithrombus stimulation energy pulses of lower energy than a defibrillation shock, but with different timing and with sufficient energy for producing atrial contraction for increasing hemodynamic blood transportation away from the atrium and for preventing thrombi formation in the atrium. For a patient suffering from a chronic or paroxysmal non-curable atrial arrhythmia, the control unit controls the stimulation energy delivering assembly to deliver the antithrombus energy without any preceding arrhythmia abolishing therapy.

The present invention relates to novel noncardiotoxic compounds and pharmaceutical compositions useful in the treatment of a variety of disorders including the treatment of depression, allergies, psychoses, cancer and gastrointestinal disorders. In particular, the present invention describes pharmaceutical compositions that mitigate life-threatening arrhythmias such as torsade de pointes. Torsade de pointes is a particular cardiac problem associated with many therapeutic agents and has been implicated as a possible cause of sudden death, particularly in those individuals with a past history of disturbances of cardiac rhythm, myocardial infarction, congenital repolarization abnormalities and cardiac risk factors such as hyperlipidemia and age. This arrhythmia is a variant of paroxysmal ventricular tachycardia associated with a prolonged QTc interval or prominent U waves on the ECG. Torsade de pointes is potentially lethal because it can progress to ventricular fibrillation, life-threatening arrhythmias or precipitate sudden death.

The invention relates to a traditional Chinese medicine composition for treating kidney stone and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: desmodium styracifolium, lygodium japonicum, chicken's gizzard-membrane, liquorice, agilawood, yellow croaker ear-stone, amber, pyrrosia lingua, radix paeoniae alba, talc, dianthus superbus, platycladi seed and lycium barbarum. The traditional Chinese medicine composition provided by the invention can effectively treat clinical symptoms such as paroxysmal lumbago with hematuresis and the like caused by kidney stone.

A combination of an antacid, alginate, and a histamine H2-receptor antagonist, and methods of using the same for providing fast and lasting relief of symptoms of episodic heartburn are provided.

The invention discloses a method for establishing a dog vagal nerve trunk stimulation-induced AF (atrial fibrillation) experimental model. The method comprises the following steps: 1, narcotization of an animal; 2, placement of an electrophysiological mapping catheter; 3, electrophysiological examination; and 4, induction and termination of AF. The method for establishing the dog vagal nerve trunk stimulation-induced AF experimental model has the beneficial effects that an acute AF animal model is manufactured through accurately positioning and stimulating dog's vagal nerve trunk, vagal nerve plexus in blood vessels and an epicardial fat pad, so that the induction rate and the stability of the model are improved; the time of duration is increased; and the manufactured dog vagus nerve-mediated AF model has the characteristics of atrial muscle and pulmonary vein electrophysiological change characteristics similarity to paroxysmal AF patients.

The invention provides an application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation. Clinic trials prove that the traditional Chinese medicine composite has the functions of tonifying qi and yin, promoting blood circulation, removing meridian obstruction, clearing away the heart fire and tranquillizing, can be used for treating paroxysmal atrial fibrillation, can obviously improve clinic symptoms and performs favourable treating effect.

The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav 1.7, a preparation method thereof and use thereof. The compound represented by the Formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof can be effectively used in the prevention or treatment of pains, for example, acute pain, chronic pain, pain from nervous disease, postoperative pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, paroxysmal extreme pain disorder (PEPD).

The invention discloses an atrial fibrillation evaluation model training method, and an atrial fibrillation evaluation method and device, and belongs to the technical field of intelligent medical treatment. The atrial fibrillation evaluation method comprises the steps that a face image including a training object is obtained, a VPPG pulse signal of the face of the training object is extracted through a video photoplethysmography method, the pulse signal is input into a noise reduction self-encoder based on a recurrent neural network, and pulse signal rhythm change features are extracted; and the pulse features are input into an atrial fibrillation classification model under the constraint of a feature scoring criterion to realize detection of the atrial fibrillation. According to the atrial fibrillation evaluation method, distorted face pulse signals can be coded into the non-interference pulse feature, and the pulse features in an atrial fibrillation attack period are emphatically monitored, so that the robustness and the accuracy of paroxysmal atrial fibrillation detection are improved, and a convenient way is provided for rapid screening of atrial fibrillation in a real environment.

To provide a therapeutic agent for diseases associated with Nav 1.7, specifically diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, urination disorders and multiple sclerosis. Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, each of R1a,R1b, R1c and R1d represents a hydrogen atom, a halogen atom, a cyano group, a C1-4 alkyl group, a C1-4 alkoxy group or the like, provided that at least one of the R1a, R1b, R1c and R1d moieties represents a C6-10 aryl group, a C6-10 aryloxy group or the like; each of R2 and R3 represents a hydrogen atom, a C1-6 alkyl group, a C3-10 cycloalkyl group or the like; R4 represents a hydrogen atom, a C1-6 alkyl group, a C3-7 cycloalkyl group or the like; m represents 1, 2 or 3; L represents a CR7R8 group; and each of R7 and R8 represents a hydrogen atom, a hydroxyl group, a C1-4 alkyl group, a C1-4 alkoxy group or the like.)

The invention discloses an anti-C5 full-human derived single-chain antibody C5B3 and application thereof. The anti-C5 full-human derived single-chain antibody C5B3 has a DNA (Deoxyribonucleic Acid) sequence as shown in SEQ ID NO:1. By adopting the antibody, formation of a membrane attacking composition in an inflammation reaction process can be remarkably inhibited, so that damage caused in the inflammation reaction process can be reduced. The invention further discloses application of the anti-C5 full-human derived single-chain antibody C5B3 in preparing medicines for treating autoimmune diseases such as ophthalmoneuromyelitis, multiple sclerosis, systemic lupus erythematosus and myasthenia gravis and / or inflammation and diseases with related symptoms caused by paroxysmal nocturnal hemoglobinuria (PNH), atypical haemolytic uraemic syndrome (AHU) and trauma.

The invention discloses a traditional Chinese medicine composition for preventing and treating paroxysmal atrial fibrillation as well as superfine powder water pills and application thereof. The medicine is prepared into the superfine powder water pills from aconitum napellus, cassia twig, raw oyster shell, rhizoma alismatis, cortex lycii radicis, magnets, radix stephaniae tetrandrae, beautiful sweetgum fruit, processed polygala tenuifolia, white mulberry root-bark, sappanwood, amber powder, radix ophiopogonis, ramulus mori, radix puerariae, tetrapanax papyriferus, turtle shell, dung beetle, pine nuts, crude dragon bone, tortoise plastron, rhizoma nardostachyos, fried wild jujube seeds, raw jujube kernels, leech, safflower, coptis chinensis, scutellaria baicalensis, American ginseng, schisandra chinensis, morinda officinalis, radices stellariae dichotomae and root of rehmannia. The traditional Chinese medicine composition disclosed by the invention is used for preventing and treating arrhythmia, accords with traditional Chinese medicine syndrome patterns such as yin-yang deficiency and deficient yang with upper manifestation, is mainly specified at patients with persistent atrial fibrillation and various arrhythmia such as palpitation, short of breath, fear of cold and the like, and is obvious in curative effects and excellent in clinical effect, and the prepared superfine powder water pills are small in size and convenient to take and carry.

The present invention relates to novel noncardiotoxic compounds and pharmaceutical compositions useful in the treatment of a variety of disorders including the treatment of depression, allergies, psychoses, cancer and gastrointestinal disorders. In particular, the present invention describes pharmaceutical compositions that mitigate life-threatening arrhythmias such as torsade de pointes. Torsade de pointes is a particular cardiac problem associated with many therapeutic agents and has been implicated as a possible cause of sudden death, particularly in those individuals with a past history of disturbances of cardiac rhythm, myocardial infarction, congenital repolarization abnormalities and cardiac risk factors such as hyperlipidemia and age. This arrhythmia is a variant of paroxysmal ventricular tachycardia associated with a prolonged QTc interval or prominent U waves on the ECG. Torsade de pointes is potentially lethal because it can progress to ventricular fibrillation, life-threatening arrhythmias or precipitate sudden death.

The invention provides a screening kit for paroxysmal supraventricular tachycardia. The screening kit comprises an optional reagent for detecting a human CACNA1B gene c.1700 A>G mutation site, whereinthe c.1700A>G mutation site of the CACNA1B gene refers to a mutation site where the 1700th basic group of the coding region of the CACNA1B gene is changed from A to G. The kit provided by the invention is designed based on the significant correlation between the c.1700A>G mutation of the CACNA1B gene and paroxysmal supraventricular tachycardia; the screening kit for paroxysmal supraventricular tachycardia is a first molecular screening kit for paroxysmal supraventricular tachycardia, can assist in diagnosis of paroxysmal supraventricular tachycardia (especially atrioventricular nodal reentrant tachycardia), is beneficial to prenatal and postnatal care, can guide doctors to apply medicines according to symptoms and has good application prospects.

The present disclosure provides methods of treating paroxysmal nocturnal hemoglobinuria (PNH) in subjects with varying exposure to eculizumab by administering R5000. The methods include methods of switching subjects from treatment with eculizumab to R5000.

The invention provides compounds which are selective PDE2 inhibitors for use in the treatment of tachycardia or tachyarrhythmia Such compounds are particularly suitable for use in the treatment of any of the following conditions: atrial tachycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, premature ventricular contractions (PVCs), ventricular fibrillation and ventricular tachycardia, and may be used alone or in combination therapy with other conventional cardiovascular drugs, e.g. beta-blockers. In particular, the invention provides compounds which are selective PDE2 inhibitors for use in the treatment of ventricular tachycardia in patients who are suffering from, or who are at risk of suffering from heart failure, CPVT or long QT syndrome.